HARBIN, China, July 7 /PRNewswire-Asia-FirstCall/ —
Renhuang Pharmaceuticals, Inc. (NYSE Amex: CBP) (“Renhuang” or the “Company”), a developer,
manufacturer and distributor of botanical products,
bio-pharmaceuticals and traditional Chinese medicines (“TCM”),
today announced that, commencing on July 2,
2010, its common stock is trading on the NYSE Amex Market
under the ticker symbol “CBP”.
On this occasion, Mr. Shaoming
Li, Chairman of the Board, Chief Executive Officer and
President of Renhuang Pharmaceuticals, Inc. made the following
statement:
“We would like to congratulate our shareholders and welcome them
to one of the world’s largest and most prestigious exchanges. Those
shareholders who have been with us for some time have seen Renhuang
grow into a major presence in botanical products,
bio-pharmaceutical products, and traditional Chinese medicines
(“TCM”), in China. We have shown
revenue growth of 24.5% CAGR in the last three years and have
launched Banlangen Granules, Compound Honeysuckle Granules, and
Qing Re Jie Du Oral Liquid in 2009 and 2010. The Company will
launch Compound Schisandra Tablets in July
2010 and Ginseng and Deer Antler Extract in August 2010. The Company continues to play
a crucial role in introducing safe and effective botanical drugs,
including its leading Siberian Ginseng (Acanthopanax) series,
biopharmaceuticals and OTC traditional Chinese medicines, with a
key focus on the development of botanical anti-depression and
nerve-regulation products.
“In additi
‘/>”/>
SOURCE